Vanderbilt Center for Antibody Therapeutics (VCAT)
-
June 8, 2022
Research probes cause of acute flaccid myelitis in children
Research that began at Vanderbilt University Medical Center has found evidence that a viral infection followed by a “robust” immune response is the cause of a polio-like paralyzing illness in children called acute flaccid myelitis (AFM). -
March 31, 2022
Crowe receives national award for COVID antibody research
Vanderbilt's James Crowe Jr., MD, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19. -
March 9, 2022
Research Staff Awards honor those who help drive science forward
Laboratory and administrative personnel at Vanderbilt University Medical Center were honored March 4 for research excellence during the 18th annual Research Staff Awards Ceremony. -
February 17, 2022
Pandemic leads to broader use of monoclonal antibodies
Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19. -
January 20, 2022
Omicron evades some but not all monoclonal antibodies: study
A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States. -
December 23, 2021
Patient receives antibodies discovered at Vanderbilt to prevent COVID-19 illness
On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19. -
December 9, 2021
Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization
The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which protects against COVID-19, discovered last year at Vanderbilt University Medical Center.